Analyses on the Impact of Tumor Burden at Progression and Changes in IMDC Risk Scores in the CLEAR Trial Prognostic Insights in Advanced RCC With Lenvatinib Plus Pembrolizumab

home / between-the-lines / analyses-on-the-impact-of-tumor-burden-at-progression-and-changes-in-imdc-risk-scores-in-the

Experts discuss the analyses on the impact of tumor burden at progression and changes in IMDC risk scores in the CLEAR trial, providing prognostic insights in advanced RCC with lenvatinib plus pembrolizumab.

EP. 1: CLEAR Trial Insights on Lenvatinib Plus Pembrolizumab: Depth of Response and Clinical Outcomes in Advanced RCC

Hans Hammers, MD, PhD;Thomas Hutson, DO, PharmD, PhD, FACP;Hannah Dzimitrowicz McManus, MD

March 10th 2025

Experts discuss insights from the CLEAR trial on lenvatinib plus pembrolizumab, focusing on depth of response and clinical outcomes in advanced renal cell carcinoma.

EP. 2: Tumor Burden Impact on Postprogression Survival: Optimizing Strategies for Maximum Response in RCC

Hans Hammers, MD, PhD;Thomas Hutson, DO, PharmD, PhD, FACP;Hannah Dzimitrowicz McManus, MD

March 10th 2025

Experts discuss the impact of tumor burden on postprogression survival, exploring strategies to optimize responses in renal cell carcinoma.